Digirad Corporation Stock Upgraded (DRAD)

NEW YORK ( TheStreet) -- Digirad Corporation (Nasdaq: DRAD) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and poor profit margins.

Highlights from the ratings report include:
  • DRAD has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 4.17, which clearly demonstrates the ability to cover short-term cash needs.
  • DIGIRAD CORP has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past two years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, DIGIRAD CORP continued to lose money by earning -$0.17 versus -$0.32 in the prior year.
  • Net operating cash flow has significantly decreased to -$1.07 million or 297.95% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 227.6% when compared to the same quarter one year ago, falling from -$0.39 million to -$1.27 million.

Digirad Corporation engages in the development and manufacture of medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications primarily in the United States. The company operates in two segments, Digirad Imaging Solutions (DIS) and Product. Digirad has a market cap of $44 million and is part of the health care sector and health services industry. Shares are up 16.8% year to date as of the close of trading on Friday.

You can view the full Digirad Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

5 Stocks Under $10 to Buy on Weakness

Buy These 11 Small-Cap Stocks for Their Solid Dividends

Cash Dividend On The Way From Digirad (DRAD)

5 Small-Cap Health Care Stocks You Never Heard of But Should Consider for 2015

3 Stocks Going Ex-Dividend Friday: DRAD, CHW, CSQ